Bioequivalence requirements in various global jurisdictions
Although the Bioequivalence (BE) requirements in many global jurisdictions have much in common, differences in certain approaches and requirements such as definitions and terms, choice of comparator (reference) product, acceptance criteria, fasted and fed studies, single and multi-dose studies, biow...
Saved in:
| Other Authors | |
|---|---|
| Format | Electronic eBook |
| Language | English |
| Published |
Cham, Switzerland :
Springer,
[2017]
|
| Series | AAPS advances in the pharmaceutical sciences series ;
v. 28. |
| Subjects | |
| Online Access | Full text |
| ISBN | 9783319680781 9783319680774 |
| Physical Description | 1 online resource |
Cover
| LEADER | 00000cam a2200000Ii 4500 | ||
|---|---|---|---|
| 001 | 97669 | ||
| 003 | CZ-ZlUTB | ||
| 005 | 20251008101101.0 | ||
| 006 | m o d | ||
| 007 | cr cnu|||unuuu | ||
| 008 | 171211t20172017sz ob 001 0 eng d | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d N$T |d GW5XE |d EBLCP |d YDX |d OCLCF |d UAB |d VT2 |d AZU |d UPM |d IOG |d MERER |d OCLCQ |d SNK |d OCLCQ |d U3W |d KSU |d AU@ |d ESU |d WYU |d OCLCQ |d LVT |d CAUOI |d UKMGB |d UKAHL |d LQU |d OCLCQ | ||
| 020 | |a 9783319680781 |q (electronic bk.) | ||
| 020 | |z 9783319680774 | ||
| 024 | 7 | |a 10.1007/978-3-319-68078-1 |2 doi | |
| 035 | |a (OCoLC)1015215259 |z (OCoLC)1015808833 |z (OCoLC)1021196691 |z (OCoLC)1026936449 |z (OCoLC)1032281342 |z (OCoLC)1048180168 |z (OCoLC)1058487605 |z (OCoLC)1066433224 |z (OCoLC)1097140822 |z (OCoLC)1105178595 | ||
| 245 | 0 | 0 | |a Bioequivalence requirements in various global jurisdictions / |c Isadore Kanfer, editor. |
| 264 | 1 | |a Cham, Switzerland : |b Springer, |c [2017] | |
| 264 | 4 | |c ©2017 | |
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a počítač |b c |2 rdamedia | ||
| 338 | |a online zdroj |b cr |2 rdacarrier | ||
| 490 | 1 | |a AAPS advances in the pharmaceutical sciences series ; |v v. 28 | |
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a Brazil -- Canada -- China -- The European Union -- India -- Bioequivalence Studies in Japan -- Middle East and North Africa (MENA) Bioequivalence Requirements -- Russia -- South Africa -- The United States of America -- World Health Organization (WHO). | |
| 506 | |a Plný text je dostupný pouze z IP adres počítačů Univerzity Tomáše Bati ve Zlíně nebo vzdáleným přístupem pro zaměstnance a studenty | ||
| 520 | |a Although the Bioequivalence (BE) requirements in many global jurisdictions have much in common, differences in certain approaches and requirements such as definitions and terms, choice of comparator (reference) product, acceptance criteria, fasted and fed studies, single and multi-dose studies, biowaivers and products not intended for absorption into the systemic circulation (locally acting medicines and dosage forms), amongst others, provide food for thought that standardisation should be a high priority objective in order to result in a harmonized international process for the market approval of products using BE. An important objective of Bioequivalence Requirements in Various Global Jurisdictions is to attempt to gather the various BE requirements used in different global jurisdictions to provide a single source of relevant information. This information from, Brazil, Canada, China, European Union, India, Japan, MENA, Russia South Africa, the USA and WHO will be of value to drug manufacturers, regulatory agencies, pharmaceutical scientists and related health organizations and governments around the world in the quest to harmonize regulatory requirements for the market approval of generic products. | ||
| 590 | |a SpringerLink |b Springer Complete eBooks | ||
| 650 | 0 | |a Drugs |x Therapeutic equivalency. | |
| 655 | 7 | |a elektronické knihy |7 fd186907 |2 czenas | |
| 655 | 9 | |a electronic books |2 eczenas | |
| 700 | 1 | |a Kanfer, Isadore, |e editor. | |
| 776 | 0 | 8 | |i Print version: |t Bioequivalence requirements in various global jurisdictions. |d Cham, Switzerland : Springer, [2017] |z 9783319680774 |z 3319680773 |w (OCoLC)1002127986 |
| 830 | 0 | |a AAPS advances in the pharmaceutical sciences series ; |v v. 28. | |
| 856 | 4 | 0 | |u https://proxy.k.utb.cz/login?url=https://link.springer.com/10.1007/978-3-319-68078-1 |
| 992 | |c NTK-SpringerBLS | ||
| 999 | |c 97669 |d 97669 | ||
| 993 | |x NEPOSILAT |y EIZ | ||